| Assessment Status | Rapid review complete |
| HTA ID | 21039 |
| Drug | Upadacitinib |
| Brand | Rinvoq® |
| Indication | For active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy. |
| Assessment Process | |
| Rapid review commissioned | 01/09/2021 |
| Rapid review completed | 11/10/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that upadacitinib not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations February 2022.
